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Abstract
Viral infections are an important cause of death worldwide. Unfortunately, there is still a lack
of antiviral drugs or vaccines for a large number of viruses, and this represents a remarkable
challenge particularly for emerging and re-emerging viruses. For this reason, the identifica-
tion of broad spectrum antiviral compounds provides a valuable opportunity for developing
efficient antiviral therapies. Here we report on a class of rhodanine and thiobarbituric deriva-
tives displaying a broad spectrum antiviral activity against seven different enveloped viruses
including an HSV-2 acyclovir resistant strain with favorable selectivity indexes. Due to their
selective action on enveloped viruses and to their lipid oxidation ability, we hypothesize a
mechanism on the viral envelope that affects the fluidity of the lipid bilayer, thus compromis-
ing the efficiency of virus-cell fusion and preventing viral entry.
Introduction
Viral infections are one of the ten leading causes of death worldwide [1]. Nowadays, although
effective antiviral strategies have been successfully developed for some important pathogens
such as HIV and HCV, antiviral drugs or vaccines are still missing for the majority of viruses.
As an example, no effective antiviral strategies are yet available for viruses causing chronic
infections such as HBV [2], as well as for tropical viruses like dengue virus that is causing 390
million infections per year [3]. A particular interest is addressed to the recent epidemics of
Ebola in Africa and Zika (ZIKV) in South America, for which, despite the huge effort to find
antivirals, the research community was not able to execute in time an efficient antiviral plan.
The majority of emerging or re-emerging viruses are zoonoses, and it has been demon-
strated that the passage among different species is easier for enveloped viruses in comparison
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with non-enveloped viruses [4, 5]. It is estimated that there are approximately 500,000
unknown mammalian viruses in animal reservoirs [6]. In this scenario, the possibility to find
antiviral molecules directed against viral envelopes is of particular interest in order to identify
broad spectrum antiviral drugs [7].
In our previous papers we reported some rhodanine and aminothiazolone derivatives
endowed with nanomolar activities against HIV-1 infected cells [8–10]. In a recent work, we
showed that our compounds were also active against HSV-1/2, while they were completely
ineffective against HPV, a nonenveloped virus [11]. These results suggested that the mode of
action of our molecules could involve the viral envelope. Compounds acting on viral envelopes
have been previously described: RAFI compounds inhibit a broad range of enveloped viruses
by inserting into viral envelopes and altering the fusion kinetics in the hemifusion stalk due to
their inverted cone structure [12]. Liposomes extracting cholesterol from viral envelopes have
been reported to inhibit HIV, HCV and HBV [13]. Virolytic antiviral peptides derived from
mastoparan were shown to inhibit different enveloped viruses acting on the envelope and
causing its detachment from the viral core [14]. The selectivity of these strategies is based on
the fact that viral envelopes are static and characterized by an absence of repair mechanisms,
in contrast with the biogenic membranes of the cells that are endowed with plenty of tools to
repair membrane damage or alteration [15]. Furthermore, since envelope lipids are derived
from host cells, it is more complicated to the virus to develop resistance to these compounds if
compared to those targeting the classical viral components; for this reason they are extremely
promising targets also for viruses with a high mutation rate.
Therefore, we investigated the activity on HSV-2 of a new series of compounds. After hav-
ing selected the most potent derivative of the series, we verified its broad spectrum activity
against an HSV-2 acyclovir-resistant strain and other six important enveloped pathogens such
as ZIKV, influenza A virus (IAV) and respiratory syncytial virus (RSV), amongst the others,
and we confirmed its complete inactivity against three non-enveloped viruses. Finally, we
investigated its mechanism of action, identifying a lipid oxidizing activity and the impairment
of viral entry of HSV-2.
Results and discussion
Chemistry
The compounds were synthesized using the one pot two step approach previously generated
by us for the synthesis of rhodanine derivatives. According to Fig 1, aldehydes 4–6 were
obtained through Suzuki reaction between commercially available iodides 1 or 2 and 5-for-
myl-2-furanylboronic acid 3. Basic hydrolysis of ester 5 provided the corresponding acid 6.
Nucleophilic substitution between trithiocarbonate and the opportune primary amine led to
the rhodanine intermediates 8a-e, which were converted into the final compounds 9a-e by
Knoevenagel condensation with aldehyde 4 or 6.
Thiobarbituric derivatives were synthesized as shown in Fig 2. Reaction between benzoyl
chloride 10, ammonium thiocyanate and the opportune amine led to intermediates 11a and
11b; consequent hydrazinolisis and coupling reaction with diethylmalonate 13 in basic condi-
tions furnished monoalkylated thiobarbituric derivatives 14a and 14b. Finally Knoevenagel
condensation with aldehyde 6 in refluxing acidic EtOH led to compounds 15a and 15b.
Evaluation of antiviral activity against HSV-2
Having proved that rhodanine derivatives belonging to this series of compounds are potential
microbicide active against HIV-1 and HSV-1/2 [11], we further investigated the inhibitory
activity against HSV-2 of the novel derivatives bearing both rhodanine and thiobarbituric
Novel broad spectrum virucidal molecules against enveloped viruses
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scaffolds. The compounds were tested with a plaquing efficiency assay, preincubating with the
virus for 1 h at 37˚C and subsequently adding the mixtures on cells. All the compounds exhib-
ited potent inhibitory activities at non-cytotoxic doses, as demonstrated by the high selectivity
indexes (Fig 3). Compound 9d, which showed the most promising antiviral activity, was sub-
jected to further investigations. The toxicity of compound 9d was evaluated at different time
points on Vero cells, and also after 96h exposure the CC50 was evaluated to be 2.09 μM con-
firming the favorable selectivity index (S1 Fig).
Fig 1. Synthesis of substituted rhodanine derivatives 9 a–e: i. Pd(PPh3)2Cl2, Na2CO3, DMF/EtOH, RT, 1h; ii. 1N NaOH (aq), MeOH/THF, reflux; iii. DME, Et3N,
MW (300 W), 90˚C, 10 min. iv. aldehyde 4 or 6, DME, MW (300 W), 110˚C, 5 min.
https://doi.org/10.1371/journal.pone.0208333.g001
Fig 2. Synthesis of monosubstituted thiobarbituric compounds 15a and 15b: i. a) NH4SCN, (CH3)2CO, 60˚C MW, min, b) opportune amine (CH3)2CO, 60˚C MW, ii.
NH2NH2; iii. Na
0, EtOH, reflux, iv. HCl, EtOH, 70˚C.
https://doi.org/10.1371/journal.pone.0208333.g002
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Compound 9d has a broad antiviral activity against enveloped viruses
Due to the lipophilic nature of the compound and the results obtained in previous works, in
which derivatives of the same series proved to be effective against HIV and HSV [11], we
investigated the spectrum of antiviral activity of 9d against different enveloped viruses (i.e.
HSV-1, HCMV, RSV, ZIKV, IAV, VSV) and non-enveloped viruses (i.e. Ad5, HPV and
HRoV). As reported in Table 1, the compound showed a potent antiviral activity against all
enveloped viruses tested at not cytotoxic doses, while it was found to be inactive against non-
enveloped viruses, suggesting a possible action on the viral envelope. Interestingly, compound
9d retained its antiviral activity also against HSV-2 acyclovir resistant strain, suggesting a dif-
ferent mechanism of action.
The antiviral activity is directed to the virus rather than the cell, but is
maintained in post treatment
We performed assays aimed at better understanding the mechanism of action. In the pretreat-
ment assay compound 9d was added on cells before the virus in order to determine if the anti-
viral activity was due to an interaction with the cells. Moreover, an assay was conducted
adding virus and compound on cells without the preincubation performed in previous assays.
The results showed in Fig 4 demonstrate that the antiviral activity of 9d is not due to an inter-
action with cells, since the compound was not active in pre-treatment assays. On the contrary,
we observed a significant reduction of activity in the during-infection assay (EC50 =
0.147 μM), if compared to the pre-incubation assay (EC50 = 6.55 nM) suggesting that the loss
of activity could be related to a competition between the viral envelope and the cell membrane
for the insertion and activity of the compound.
We then investigated whether compound 9d was able to inhibit multiple cycles of infection,
in viral yield reduction assays, when added post infection. As shown in Fig 5, in this condition
the compound retained a good antiviral activity, suggesting possible therapeutic uses.
Fig 3. Antiviral activity against HSV-2. �EC50 half maximal effective concentration; ˚EC90 90% effective concentration; #C.I. confidence interval; †CC50
half maximal cytotoxic concentration; ‡SI selectivity index; n.a. not assessable. 9d n = 5, other compounds n = 2.
https://doi.org/10.1371/journal.pone.0208333.g003
Table 1. Spectrum of antiviral activity of compound 9d.
Type of virus Virus EC50� [nM] (95% C.I.#) EC90˚ [nM] (95% C.I.#) CC50
† [μM] SI‡
Enveloped HSV-2a 1.60 (1.54–1.66) 24.3 (18.7–31.5) 2.09 1306
Enveloped HSV-1 2.18 (0.91–5.20) 35.1 (6.70–184) 2.09 958.7
Enveloped HCMV 4.22 (2.89–6.16) 31.3 (13.3–76.7) 5.24 1241
Enveloped RSV 54.8 (48.2–62.2) 221 (162–301) 17.04 291.8
Enveloped ZIKAV 69.9 (57.3–85.3) 147 (81–240) 8.85 126.6
Enveloped IAV 66.1 (54.7–80.1) 301.2 (201.3–470) 135.7 2053
Enveloped VSV 13.2 (9.58–18.3) 117 (57.2–239) 24.84 1881
Non enveloped HPV-16 n.a. n.a. 94.23 n.a.
Non enveloped Ad5 n.a. n.a. 94.23 n.a.
Non enveloped HRoV n.a. n.a. 156.1 n.a.
aAcyclovir resistant strain
�EC50 half maximal effective concentration
˚EC90 90% effective concentration
#C.I. confidence interval
†CC50 half maximal cytotoxic concentration
‡SI selectivity index; n.a. not assessable. n = 2.
https://doi.org/10.1371/journal.pone.0208333.t001
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Virucidal activity
To further elucidate the mechanism of action we performed a virucidal assay in which 9d was
incubated with the virus at 10 μM 5μM or 1μM concentration for different times (Fig 6A) or
for 1h with serial dilutions of compound (Fig 6B); subsequently, the mixture was titrated on
cells and the viral titer was evaluated at dilutions at which the compound concentration was
known not to be active in plaquing efficiency assays. In these conditions it was possible to
observe that the viral infectivity in presence of the compound was decreased at 15’ post treat-
ment and completely abrogated from 30’ on when the virus was exposed to 10 μM of
Fig 4. Time of addition assays. Compound 9d was added on cells 2 h before infection (PRE-TREATMENT CELLS) and subsequently the
inocula were removed and cells were infected or compound and virus were added simultaneously on cells (DURING INFECTION) or
after 1 h pre-incubation between the virus and the compound (PRE-TREATMENT VIRUS). Cells were fixed and stained 24 h later and
plaques were counted. The percentage of infection was calculated comparing treated wells to wells treated with equal volumes of solvent.
n = 3.
https://doi.org/10.1371/journal.pone.0208333.g004
Fig 5. Viral yield reduction. Cells were infected with HSV-2 (MOI 0.01) and after the removal of inoculum they were
treated with increasing concentrations of compound. At 24 hpi when the untreated wells showed extensive
cytopathology, supernatants and cells were harvested and subsequently titrated with plaque assay. The percentage of
infection was calculated comparing viral titer in treated wells and wells treated with equal volumes of solvent. n = 4.
https://doi.org/10.1371/journal.pone.0208333.g005
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compound, and at lower doses (Fig 6A). While after 1h of exposure, the EC50 was 37.3 nM
(Fig 6B). The irreversibility of the mechanism was also tested with an assay in which the com-
pound was incubated with the virus for 1h and subsequently the mixture has been diluted in
drug free medium for additional 1, 2, 3 or 4 hours before the addition on cells (S2 Fig). Also in
this condition the infectivity was not regained further verifying the permanent virucidal
activity.
Since the observed irreversible effect can be exerted at different stages of viral infection, we
investigated more in detail if compound 9d produced a physical disruption of the virus, thus
preventing its attachment to the cells or a successive irreversible modification. We performed
entry and binding assays, evaluating the amount of bound virus through immunostaining or
qPCR. The results shown in Fig 7A, 7B and 7C, demonstrate that the compound is not altering
viral binding capability, differently from heparin, a known attachment inhibitor [16]. On the
contrary, when entry assays were performed, it was possible to observe a reduction in the
amount of virus associated to the cells (Fig 7D). With this assay, the signal from the virus
could be related to virus in the cytoplasm or blocked in the endosomes, since the treatment
with acidic glycine is affecting only the virus at the surface of the cell. For this reason we per-
formed also an in immunofluorescence (IF) in which it was possible to visualize that there is
virus signal in discrete dots, possibly endosomes, while in the control the viral signal is diffused
in the cytoplasm (Fig 7E), supporting the hypothesis that part of the virus could be blocked in
endosomes due to an impaired fusion.
In vitro determination of the compound peroxidative capability
Due to the chemical structure of compound 9d and its affinity for lipids, we envisioned that its
mechanism of action might involve the peroxidation of viral phospholipids, which would lead
to altered fusion properties of enveloped viruses. To assess this hypothesis, we carried out an
in vitro lipoperoxidation assay based on the oxidation of linoleic acid as model lipid substrate,
incorporated in a DPPC liposomes. The lipid peroxidation was evaluated by monitoring the
production of the lipid degradation end-product malondialdehyde (MDA). After the exposure
to compound 9d, the linoleic acid underwent a remarkable lipid peroxidation in the liposome
system (Fig 8). The results of the TBA assay suggest the peroxidant activity of the compound.
The peroxidation capability of 9d was further confirmed by the reduction of linoleic acid per-
oxidation extent in a control sample in which in the preparation of liposomes, an antioxidant
such as (±)-α-tocopherol, was added. Interestingly the addition of 0.05% w/w (±)-α-
Fig 6. Virucidal activity. A) 105 pfu of HSV-2 were incubated for 0, 15’, 30’, 45’ or 60’ at 37˚C with 10 μM, 5 μM or
1 μM of compound and subsequently titrated on Vero cells. B) 105 pfu of HSV-2 were incubated with different doses of
compounds 9d for 1h and subsequently titrated on Vero cells. Viral titers were calculated at dilutions of compounds at
which, in plaquing efficiency assay, did not show any inhibitory activity. The percentage of infection was calculated
comparing viral titer in treated wells and wells treated with equal volumes of solvent. Results show the mean and SD or
square roots of the sum of squares, n = 6 for 60’ and n = 2 for other conditions.
https://doi.org/10.1371/journal.pone.0208333.g006
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tocopherol in the system reduced the peroxidation of linoleic acid of 50.5%. Blank samples
produced negligible lipid peroxidation.
Conclusions
In this work we demonstrated that the series of compounds herein reported, and in particular
compound 9d, are endowed with a broad-spectrum activity against a panel of seven different
Fig 7. Binding and entry assays. (A-B-C) HSV-2 (MOI 10) was incubated for 1 h at 37˚C with 10 μM of compound and subsequently added for 2 h
on Vero cells at 4˚C. Subsequently cells were subjected to qPCR (A) or immunostaining (B) or IF (C). (D-E) HSV-2 (MOI 10) was incubated for 1 h at
37˚C with 10 μM of compound and subsequently added for 1 h on Vero cells at 4˚C and then shifted at 37˚C for 1.5 h (D) or 4 h (E) subsequently cells
were fixed and subjected to ICC (D) or IF (E). UT = untreated �� p<0.001 ��� p<0.0005 ���� p<0.0001. n = 3.
https://doi.org/10.1371/journal.pone.0208333.g007
Fig 8. In vitro determination of lipid peroxidation capability. MDA (micromoles/mg) produced from the linoleic
acid peroxidation after exposure to compound 9d in the presence and in the absence of (±)-α-tocopherol. �� p<0.01
NaCl 0.9% and DMSO are blank samples prepared without the addition of 9d and (±)-α-tocopherol. n = 3.
https://doi.org/10.1371/journal.pone.0208333.g008
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enveloped viruses including a HSV-2 acyclovir resistant strain, due to an irreversible mecha-
nism that impairs viral entry into the host cell. The selective activity on enveloped viruses and
the lipid peroxidation capability of the compound suggest a mechanism of action on the viral
envelope that is affecting viral and cell membrane fusion. These results open interesting possi-
ble applications for these molecules as antivirals or as components of microbicidal prepara-
tions for topical use. This is of particular interest if we consider that all the recent epidemics of
emerging and re-emerging viruses are caused by enveloped viruses such as Ebola virus, Lassa
virus, Zika virus, SARS and MERS Coronavirus and avian flu [3], without considering the
threatening infections of Hendra and Nipah viruses and the emergence of novel mutant
strains. Finally, the activity of the reported compounds against HIV [6], HSV-1, HSV-2 and
ZIKV, which can be all transmitted through sexual activity, suggest a possible use of this class
of compounds as vaginal microbicide components.
Materials and methods
Chemistry
General information. All commercially available chemicals were used as purchased.
Anhydrous reactions were run under a positive pressure of dry N2. Thin-layer chromatogra-
phy (TLC) was carried out using Merck TLC plates: silica gel 60 F254. Chromatographic puri-
fications were performed on columns packed with Merck 60 silica gel, 23–400 mesh, for the
flash technique. 1H and 13C NMR spectra were recorded at 400 MHz on a Bruker Avance
DPX400 spectrometer. Melting points were measured using a Gallenkamp melting point appa-
ratus and are uncorrected. Microwave irradiation experiments were conducted using a CEM
Discover Synthesis Unit (CEM Corp., Matthews, NC, USA). The instrument consists of a con-
tinuous focused microwave power delivery system with operator-selectable power output from
0 to 300 W. The temperature of the contents of the vessel was monitored with a calibrated IR
temperature control mounted under the reaction vessel. All experiments were performed
using a stirring option, whereby the contents of the vessel were stirred by a rotating magnetic
plate located below the floor of the microwave cavity and a teflon-coated magnetic stir bar in
the vessel.
General procedure for the synthesis of aldehydes 4 and 5. Methyl-4-iodosalycilate 1 or
4-Chloro-3-iodobenzotrifluoride 2 (1.00 mmol) and 5-formyl-2-furan boronic acid 3 were dis-
solved in 10 mL of DMF and 15 mL of EtOH. The reaction mixture was stirred for 10 min
under N2, then Pd(PPh3)2Cl2 (0.10 mmol) was added and finally Na2CO3 2M (6.00 mmol).
The reaction mixture (light-orange) was stirred under N2 at room temperature. After 1h the
reaction went to completion and was quenched with H2O and 2N HCl; then EtOAc was added
and the mixture was stirred until the two layers became clear. The aqueous layer was extracted
three times with EtOAc, then the organic phase was washed several times with H2O and brine,
dried over Na2SO4, filtered and evaporated under reduced pressure.
5-(2-chloro-5-(trifluoromethyl)phenyl)furan-2-carbaldehyde (4). The crude product
was purified by flash chromatography using PE/EtOAc = 4:1 as eluent to yield the wished
product 4 as a brown solid (yield: 20%); mp = 157˚C (decomposition); 1H NMR (400 MHz,
CDCl3) δ 9.73 (s, 1H), 8.23 (s, 1H), 7.76–7.45 (m, 2H), 7.42–7.28 (m, 2H)ppm. MS (ESI): m/z
273.0 [M-H]-;
Methyl 4-(5-formylfuran-2-yl)-2-hydroxybenzoate (5). The crude product was purified
by flash chromatography using PE/EtOAc = 4:1 as eluent to yield the wished product 5 as a
light orange solid (yield: 96%); mp = 150˚C (decomposition); 1H NMR (CDCl3, 400 MHz): ð =
10.84 (s, 1H), 9.69 (s, 1H), 7.91–7.88 (d, 1H, J = 12 Hz), 7.40–7.39 (d, 1H, J = 4 Hz), 7.35–7.32
(m, 3H), 6.94–6.93 (d, 1H, J = 4Hz), 3.97 (s, 3H); 13C (CDCl3, 100 MHz): ð = 177.47, 161.69,
Novel broad spectrum virucidal molecules against enveloped viruses
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157.37, 152.53, 135.17, 130.58,122.56, 115.74, 113.73, 112.82, 109.84, 52.40, 29.59; MS (ESI):
m/z 245.0 [M-H]-;
4-(5-Formylfuran-2-yl)-2-hydroxybenzoic acid (6). Compound 5 was dissolved in 25
mL of CH3OH, then a solution of NaOH 1M (5.00 mmol) was added dropwise, after the reac-
tion mixture was heated at reflux. The reaction mixture was stirred overnight until completion
(TLC). Organic solvent was removed under reduced pressure, then some water was added and
the aqueous layer was extracted three times with Et2O; the aqueous layer was then acidified to
pH 1 with HCl 6N and a precipitated appeared. (6) was obtained as a brown-red solid (yield:
95%); mp = 230˚C (decomposition); 1H NMR (DMSO, 400 MHz): ð = 9.63 (s, 1H), 7.88–7.86
(d, 1H, J = 8 Hz), 7.66–7.65 (d, 1H, J = 4 Hz), 7.45–7.39 (m, 3H); 13C NMR (DMSO, 100
MHz): ð = 178.72, 171.68, 161.69, 156.82, 152.63, 135.11, 131.72, 125.14, 116.02, 114.06,
113.29, 111.53; MS (ESI): m/z 231.0 [M-H]-;
General procedure for the synthesis of final compounds 9a-e. To a solution of bis(car-
boxymethyl)trithiocarbonate (0.22 mmol) in DME (1.0 mL) were added TEA (0.22 mmol) and
the opportune amine (0.22 mmol). The reaction mixture was heated at 90˚C for 10 min under
microwave irradiation. After this time, the aldehyde 6 (0.22 mmol) was added and the mixture
was heated at 110˚C for 5 min under microwave irradiation. The reaction mixture was evapo-
rated to dryness, then MeOH and a drop of HCl 2N were added; the final rhodanine deriva-
tives were obtained as a pure precipitate, isolated by filtration, washed with water and hexane,
and finally dried under high vacuum.
(Z)-4-(5-((3-(2-(1H-Indol-3-yl)ethyl)-4-oxo-2-thioxothiazolidin-5- ylidene)methyl)
furan-2-yl)-2-hydroxybenzoic acid (9a). (Yield: 55%); Yellow-brown solid; mp = 254˚C
(decomposition); 1 H NMR: ((CD3)2CO, 400 MHz) δ = 8.00–7.98 (d, 1H, J = 8.4 Hz), 7.76–
7.74 (d, 1H, J = 8 Hz), 7.64 (s, 1H), 7.47–7.33 (m, 5H), 7.22 (s, 1H), 7.11–7.02 (m, 2H) 4.41–
4.37 (m, 2H), 3.19–3.15 (m, 2H); 13C NMR (DMSO, 100 MHz): δ = 194.15, 171.77, 166.77,
161.81, 156.64, 150.49, 136.64, 134.91, 131.77, 127.45, 123.59, 123.10, 121.47, 120.25, 118.86,
118.53, 118.33, 115.53, 113.52, 113.09, 112.40, 111.90, 110.38, 45.23, 22.82; MS (ESI): m/z
489.0 [M-H]-;
(Z)-4-(5-((3-(4-bromophenethyl)-4-oxo-2-thio-oxothiazolidin-5-ylidene)methyl)furan-
2-yl)-2-hydroxybenzoic acid (9b). (Yield: 89%); Brown solid. Mp = 275˚C (decomposition);
1H NMR: (DMSO, 400 MHz) δ = 7.93–7.91 (d, 1H, J = 8.4 Hz), 7.64 (s, 1H), 7.48–7.46 (m,
3H), 7.39–7.36 (m, 3H), 7.18–7.16 (m, 2H), 4.24–4.21 (m, 2H), 2.96–2.93 (m, 2H) ppm. 13C
NMR (DMSO, 100 MHz): δ = 194.07, 171.54, 166.68, 161.86, 156.87, 150.49, 137.55, 134.85,
131.72, 131.50, 131.34, 123.05, 120.02, 119.43, 118.48, 115.51, 114.05, 112.90, 112.53, 45.32,
31.96 ppm. MS (ESI): m/z 529.0 [M-H]-. Purity: 97.5%.
(Z)-2-hydroxy-4-(5-((3-(4-methoxyphenethyl)-4-oxo-2-thioxothiazolidin-5-ylidene)
methyl)furan-2-yl)benzoic acid (9c). (Yield: 79%); Yellow solid. Mp = 265˚C (decomposi-
tion); 1H NMR: (DMSO, 400 MHz) δ = 7.90–7.88 (d, 1H, J = 8.0 Hz), 7.60 (s, 1H), 7.45–7.44
(d, 1H, J = 3.6 Hz), 7.36–7.33 (m, 3H), 7.13–7.10 (d, 2H, J = 8.4 Hz), 6.85–6.83 (d, 2H, J = 8.4
Hz), 4.18–4.14 (m, 2H), 3.70 (s, 3H), 2.89–2.85 (m, 2H) ppm. 13C NMR (DMSO, 100 MHz): δ
= 193.99, 171.74, 166.65, 161.81, 158.40, 156.68, 150.46, 134.89, 131.76, 130.05, 129.82, 123.13,
120.00, 118.39, 115.53, 114.33, 113.60, 113.06, 112.42, 55.37, 45.85, 31.67 ppm. MS (ESI): m/z
481.0 [M-H]-. HPLC: purity: 98.5%.
(Z)-2-hydroxy-4-(5-((3-(4-isopropylphenethyl)-4-oxo-2-thioxothiazolidin-5-ylidene)
methyl)furan-2-yl)benzoic acid (9d). (Yield: 87%); Orange solid. Mp = 259˚C (decomposi-
tion); 1H NMR: (DMSO, 400 MHz) δ = 7.89–7.87 (d, 1H, J = 8.0 Hz), 7.59 (s, 1H), 7.43–7.40
(m, 2H), 7.34–7.31 (m, 2H), 7.15–7.12 (m, 4H), 4.18–4.14 (m, 2H), 2.89–2.85 (m, 2H), 1.39 (s,
1H), 1.17–1.15 (m, 6H) ppm. 13C NMR (DMSO, 100 MHz): δ = 193.97, 171.77, 166.62, 161.83,
156.69, 150.45, 147.10, 135.29, 134.86, 131.72, 128.91, 126.83, 125.16, 123.13, 120.02, 118.36,
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115.96, 115.51, 113.58, 113.03, 112.41, 45.68, 33.42, 32.18, 24.26 ppm. MS (ESI): m/z 493.0 [M-
1]-. HPLC: purity: 98.0%.
(Z)-5-((5-(2-chloro-5-(trifluoromethyl)phenyl)furan-2-yl)methylene)-3-(4-fluoroben-
zyl)-2-thioxothiazolidin-4-one 7 (9e). (Yield: 20%); Orange solid. Mp = 259˚C (decomposi-
tion); 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.4 Hz, 1H), 7.56–7.50 (m, 2H), 7.40 (dd,
J = 10.3, 6.0 Hz, 3H), 7.31–7.23 (m, 4H)ppm. 13C NMR (DMSO, 100 MHz): δ = 193.97, 171.77,
166.62, 161.83, 156.69, 150.45, 147.10, 135.29, 134.86, 131.72, 128.91, 126.83, 125.16, 123.13,
120.02, 118.36, 115.96, 115.51, 113.58, 113.03, 112.41, 45.68, 33.42, 32.18, 24.26 ppm. MS
(ESI): m/z 496.0 [M-H]-. HPLC: purity: 98.0%.
General procedure for the synthesis of compounds 11a and 11b. Benzoylchloride 10
(4.31 mmol, 1.00 eq) was dissolved in 3 mL of acetone. To this, NH4SCN (5,17 mmol, 1.2 eq)
was added in one portion and the mixture irradiated at 60˚C for 15 min at the microwave.
After this time, the opportune amine (1.00 eq) respectively benzylamine for 8a, and phenethy-
lamine for 8b, was added, and the mixture was irradiated for further 15 min at the microwave.
The resulting suspension was filtered, and the precipitate washed with H2O and CH3OH, to
furnish pure 8a and 8b as white solids.
N-(benzylcarbamothioyl)benzamide (11a). Yield 50% white solid. 1H NMR: (400 MHz
CDCl3) δ (ppm) 11.05 (bs, 1H), 9.27 (bs, 1H), 7.80 (d, 2H, J = 8.4 Hz), 7.57 (t, 1H, J = 14.8 Hz),
7.45 (t, 2H, J = 15.2 Hz), 7.39–7.30 (m, 5H), 4.91 (d, 2H, J = 5.2 Hz)ppm. MS: (ESI) m/z 268.9
[M-H]-
N-(phenethylcarbamothioyl)benzamide (11b). Yield 47% white solid. 1H NMR: (400
MHz CDCl3) δ (ppm) 10.78 (bs, 1H), 9.09 (bs, 1H), 7.80 (d, 2H, J = 7.2 Hz), 7.60 (t, 1H, J =
14.8 Hz), 7.48 (t, 2H, J = 15.6 Hz), 7.36–7.23 (m, 5H), 3.95 (q, 2H, J = 20.4 Hz), 3.03 (t, 2H, J =
14.4 Hz)ppm. MS: (ESI) m/z 282.9 [M-H]-
General procedure for the synthesis of compounds 12a and 12b. The opportune thiour-
eido derivative (11a or 11b) (1.61 mmol) was dissolved in 10 mL of hydrazine monohydrate.
The solution was stirred at RT for 3 h. Then 5 mL of fuming hydrochloric acid were added and
the mixture was extracted with CH2Cl2 (3 x 15 mL). The organic phase was washed with
Na2CO3 (aq. sol.) (2 x 50 mL), and dried over Na2SO4. The solvent was removed at reduced
pressure and the corresponding residue purified by flash chromatography (AcOEt/CH2Cl2
1:1).
1-benzylthiourea (12a). Yield 80% white solid. 1H NMR: (400 MHz DMSO-d6) δ 7.94
(bs, 1H), 7.33–7.21 (m, 5H), 7.03 (bs, 2H), 4.60 (s, 2H)ppm; MS: (ESI) m/z 166.9 [M+H]+;
1-phenethylthiourea (12b). Yield 95% white solid.1H NMR: (400 MHz DMSO-d6) δ 7.33
(t, 2H, J = 14.4 Hz), 7.26 (t, 1H, 6.8 Hz), 7.21 (d, 2H, J = 7.2 Hz), 5.68 (bs, 2 H), 2,91 (t, 2H, J =
14.0 Hz)ppm. MS: (ESI) m/z 178.9 [M-H]-
General procedure for the synthesis of compounds 14a and 14b. Sodium metal (3,61
mmol, 3 eq) was dissolved in anhydrous EtOH (10 mL), then the opportune thiourea com-
pound (12a or 12b) (1.20 mmol) and diethylmalonate 13 (2.41 mmol) were added subse-
quently, and the mixture was refluxed under Argon atmosphere. The solvent was removed at
reduced pressure and the corresponding residue was solubilized in water. The mixture was
acidified at pH 2 with HCl 1N and filtered. The residue was then purified by flash chromatog-
raphy (CH2Cl2/CH3OH 8:2).
1-benzyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (14a). Yield 80% red solid. 1H
NMR: (400 MHz DMSO-d6) δ 10.54 (bs, 1H), 7.23–7.15 (m, 5H), 5.39 (s, 2H), 4.30 (s, 1 H)
ppm. MS: (ESI) m/z 232.9 [M-H]-
1-phenethyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (14b). Yield 80% white
solid. 1H NMR: (400 MHz DMSO-d6) δ (ppm) 10.76 (bs, 1H), 7.29–7.19 (m, 5H), 4.33 (t, 2H, J
= 16.0), 3.14 (s, 1 H), 2.83 (t, 2H, J = 16.0)ppm. MS: (ESI) m/z 246.9 [M-H]-
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General procedure for the synthesis of compounds 15a and 15b. Compound 6 (0,22
mmol, 1 eq) and compound 13a or 13b (0.22 mmol, 1 eq) were suspended in EtOH (6 mL); to
this, 3 drops of HCl (conc.) were added and the mixture was stirred at 70˚C overnight. After
this time 3 mL of HCl were added and the resulting precipitate was filtered at reduced pressure
to give a solid that was washed with H2O, CH3OH and hexane.
(Z)-4-(5-((1-benzyl-4,6-dioxo-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl)
furan-2-yl)-2-hydroxybenzoic acid (15a). (Yield 53%) red solid, 1H NMR: (400 MHz
DMSO-d6) δ 8.57 (d, 1H, 3,6), 8.12 (s, 1H), 7.84 (d, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 3.6 Hz),
7.45–7.42 (m, 2H), 7-29-7.20 (m, 5H), 5.52 (s, 2H)ppm, 13C NMR: (101 MHz DMSO-d6) δ
179.42, 171.68, 162.05, 161.72, 160.30, 159.71, 158.73, 151.34, 138.28, 136.86, 134.45, 131.61,
130.83, 128.57, 127.31, 116.43, 114.46, 113.68, 113.38, 113.26, 49.55 ppm. MS: (ESI) m/z 446.7
[M-H]-
(Z)-4-(5-((4,6-dioxo-1-phenethyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl)
furan-2-yl)-2-hydroxybenzoic acid (15b). (Yield 80%) brown solid, 1H NMR: (400 MHz
DMSO-d6) δ 8.59 (s, 1H), 8.14 (s, 1H), 7.88 (d, 1H, J = 8.0), 7.62 (d, 1H, J = 3.6), 7.52–7.49 (m,
2H), 7-33-7.22 (m, 5H), 4.45 (m, 2H, J = 22.0 Hz), 2.91 (q, 2H, 22.4)ppm; 13C NMR: (101 MHz
DMSO-d6) δ 178.97, 171.69, 161.79, 160.38, 159.64, 158.81, 151.34, 151.19, 138.84, 137.63,
134.53, 131.70, 130.72, 128.96, 126.86, 116.47, 114.63, 114.46, 113.73, 48.96, 32.96 ppm, MS:
(ESI) m/z 460.8 [M-H]-
Cells
African green monkey fibroblastoid kidney cells (Vero, ATCC CCL-81), human epithelial cells
(Hep-2) (ATCC CCL-23) African green monkey kidney epithelial (MA-104) cells (ATCC
CRL-2378.1), Madin Darby Canine Kidney (MDCK ATCC CCL-34) were grown as monolay-
ers in Eagle’s minimal essential medium (MEM) (Gibco/BRL, Gaithersburg, MD) supple-
mented with 10% heat inactivated fetal calf serum (FCS) and 1% antibiotic-antimycotic
solution (Zell Shield, Minerva Biolabs GmbH, Berlin, Germany). Low-passage human embry-
onic lung fibroblasts (HELFs) were grown as monolayers in Eagle’s minimal essential medium
(Gibco-BRL) in the same conditions as described above with the addition of 1 mM sodium
pyruvate. Human epithelial adenocarcinoma HeLa cells (ATCC CL-2TM) were propagated in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented as described above. The 293TT
cell line, derived from human embryonic kidney cells transformed with the simian virus 40
(SV40) large T antigen, was cultured as monolayer in medium in DMEM supplemented with
Glutamax-I (Invitrogen, Carlsbad, CA) and nonessential aminoacids.
Viruses
Clinical isolates of HSV-1 and HSV-2 were kindly provided by Prof. M. Pistello, University of
Pisa, Italy. HSV-1 and HSV-2 strains were propagated and titrated by plaque assay on Vero
cells. A HSV-2 strain with phenotypic resistance to acyclovir was generated by serial passage in
the presence of increasing concentrations of acyclovir and tested for acyclovir resistance with
dose-response inhibition assay with an EC50 of 319 μM, as previously described [17]. HCMV
strain Towne was kindly provided by Prof. W. Brune, Heinrich Pette Institut, Hamburg, Ger-
many; it was propagated and titrated by plaque assay on HELF cells. RSV strain A2 (ATCC
VR-1540) was propagated in Hep-2 and titrated by the indirect immunoperoxidase staining
procedure using an RSV monoclonal antibody (Ab35958; Abcam, Cambridge, United King-
dom), as described previously [15]. Human rotavirus strain Wa (ATCC VR-2018) was acti-
vated with 5 mg/mL porcine pancreatic trypsin type IX (Sigma, St. Louis, Mo.) for 30 min at
37˚C and propagated in MA104 cells using MEM containing 0.5 mg trypsin per mL, as
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described previously [18]. VSV (ATCC VR-1238) was propagated on Vero cells and titrated by
plaque assay. Zika virus (PRVABC59) was kindly provided by Marco Alves and was propa-
gated and titrated by plaque assay on Vero cells. IAV H1N1 isolated from a clinical specimen
was propagated and titrated on MDCK. Adenovirus 5 encoding GFP (GFP-Ad5), with a E1/E3
deletion, was purchased from Vector Biolabs (Philadelphia, PA, USA). HPV-16 pseudovirions
were produced with 293TT as previously described [19] and their concentration was assessed
on Hela cells. Virus stocks were maintained at -80˚C.
Cell viability
Cell viability was measured using the MTS [3- (4,5-dimethylthiazol-2-yl)-5- (3 carboxy meth-
oxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. Cell cultures were seeded in 96-well
plates and were incubated with different concentrations of compounds in duplicate under the
same experimental conditions described for the antiviral assays, (i.e. if the incubation time of
the compound on cells was carried for 2 hours and then the evaluation of the antiviral activity
was done 72h later, the same timing was used for the cytotoxicity assays, in order to exclude
any toxicity effect in the antiviral evaluation). Cell viability was determined using the CellTiter
96 Proliferation Assay Kit (Promega, Madison, WI, USA) according to the manufacturer’s
instructions. Absorbances were measured using a Microplate Reader (Model 680, BIORAD) at
490 nm. The effect on cell viability at different concentrations of the compound was expressed
as a percentage, by comparing absorbances of treated cells with those of cells incubated with
culture medium and equal volumes of vehicle. The 50% cytotoxic concentrations (CC50) and
95% confidence intervals (CIs) were determined using Prism software (Graph-Pad Software,
San Diego, CA). For compound 9d a continuous incubation of 1, 2, 3 and 4 days on Vero cells
was carried in order to evaluate the toxicity after long exposure the results are shown in S1 Fig
and Fig 3.
HSV, VSV and ZIKV inhibition assays
The antiviral effect on HSV and VSV and ZIKV infection was evaluated by plaquing efficiency
assay. Vero cells were pre-plated 24 h in advance in 24-well plates at a density of 105 cells.
Increasing concentrations of compounds were mixed with HSV-2 (MOI 0.001 pfu/cell) or
HSV-2 acyclovir resistant (MOI 0.001) or HSV-1 (MOI 0.0005) or VSV (MOI 0.005) or ZIKV
(MOI 0.005) and incubated for 1 hour at 37˚C. The mixtures were subsequently added to the
cells, which were then incubated at 37˚C for 2 h. The virus inoculum was then removed and
the cells washed and overlaid with a medium containing 1.2% methylcellulose (Sigma). After
further incubation at 37˚C for 24 h (HSV-2 and VSV) or 48 h (HSV-1) or 72h (ZIKV), cells
were fixed and stained with 0.1% crystal violet in 20% ethanol and viral plaques counted. The
effective concentration producing 50% reduction in plaque formation (EC50) was determined
using Prism software by comparing drug-treated with wells treated with medium and solvent.
The selectivity index (SI) was calculated by dividing the CC50 by the EC50 value.
HCMV inhibition assays. HELF cells were pre-plated in a 96-well plate. The following
day increasing concentrations of compounds were mixed with HCMV (MOI 0.005) and incu-
bated for 1 h at 37˚C. The mixtures were subsequently added to the cells, which were then
incubated at 37˚C for 3 h; monolayers were then washed and overlaid with 1.2% methylcellu-
lose medium supplemented with 3% FCS and 1mM sodium pyruvate. After five days incuba-
tion, cells were observed under an inverted Zeiss LSM510 fluorescence microscope (Zeiss,
Oberkochen, Germany) and the percentages of infection were calculated by comparing GFP
positive cells in treated and untreated wells.
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RSV inhibition assays. HeP-2 cells were pre-plated in a 96-well plate. The following day
increasing concentrations of compounds were mixed with RSV (MOI 0.005) and incubated
for 1 h at 37˚C. The mixtures were subsequently added to the cells, which were then incubated
at 37˚C for 3 h; monolayers were then washed and overlaid with 1.2% methylcellulose
medium. 72 h later cells were fixed and subjected to specific immunostaining using an RSV
monoclonal antibody (Ab35958; Abcam, Cambridge, United Kingdom) in order to visualize
syncytia. Percentages of infection were calculated by comparing numbers of syncytia in treated
and untreated wells.
HRoV inhibition assays. MA104 cell were plated in 96-well trays. The following day virus
infectivity was activated by adding 5 μg porcine trypsin (Sigma)/mL for 30 min at 37˚C.
Increasing concentrations of compounds were mixed with HRoV (MOI 0.02) and incubated
for 1 h at 37˚C. The mixtures were subsequently added to the cells, which were then incubated
at 37˚C for 1 h; monolayers were then washed and overlaid with medium. After 16 h, cells
were fixed with cold acetone–methanol and viral titers were determined by indirect immunos-
taining using the monoclonal antibody mab-0036 (specific for human 41 kDa inner capsid
protein–VP6 –of rotavirus) purchased from Covalab (Villeurbanne, France) and the UltraTech
HRP Streptavidin-Biotin Detection System (Beckman Colter).
HPV-16 and Ad5 inhibition assays. HeLa cells were plated in 96-well plates. The follow-
ing day, increasing concentrations of compounds were mixed with HPV-16 (approximately 1
ng/mL L1) or Ad5 (MOI 0.02) and incubated for 1 h at 37˚C. The mixtures were subsequently
added to the cells, which were then incubated at 37˚C for 72 h. The GFP-expressing infected
cells were observed under an inverted Zeiss LSM510 fluorescence microscope (Zeiss, Oberko-
chen, Germany) and the percentages of infection were calculated by comparing GFP positive
cells in treated and untreated wells.
IAV H1N1 inhibition assays. MDCK cells were pre-plated in 96-well plates. The follow-
ing day, increasing concentrations of compounds were mixed with IAV (MOI 0.05) and incu-
bated for 1 h at 37˚C. The mixtures were subsequently added to the cells for 1 h at 37˚C, after a
washout cells were overlaid with medium for 16 h at 37˚C. Cells were then fixed and subjected
to specific immunostaining using a Flu A monoclonal antibody (Merck 5001) in order to visu-
alize infected cells. Percentages of infection were calculated by comparing numbers of infected
cells in treated and untreated wells.
Mechanism of action study
Vero cells were subjected to different assays:
Pretreatment: cells were pretreated for 2 h at 37˚C with increasing concentrations of com-
pounds, the inocula were then removed, cells washed and HSV-2 was added on cells for 2 h at
37˚C. Subsequently the same protocol described above was followed.
During infection: Cells were subjected to the same experiment described above without the
pre-incubation between compounds and virus. Post treatment: Cells were infected with HSV-
2 (MOI 0.01) for 2 h at 37˚C, the viral inoculum was removed and cultures were exposed to
different compound concentrations and incubated until control cultures displayed extensive
cytopathology. Supernatants and cells were harvested and cell-free virus infectivity titers were
determined in duplicate by plaque assay in Vero cell monolayers. Percent inhibition was deter-
mined by comparing the titer measured in the presence of the compounds to that measured in
untreated wells.
Binding: Cells were plated in 96 well plates. The following day 10 μM of compound and
HSV-2 (MOI 10) were incubated for 1 h at 37˚C and subsequently added on cells for 2 h at
4˚C. Cells were then fixed with 4% paraformaldehyde, air dried, and blocked with 5% bovine
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serum albumin (BSA) in phosphate-buffered saline (PBS)–Tween. Bound virus was detected
using the polyclonal HSV-2 antibody (Dako, Denmark) (diluted 1:250) incubated for 1 h at
room temperature, washed three times with PBS-Tween, and incubated for 1 h at 37˚C with
anti-rabbit conjugated to horseradish peroxidase (1:500). At the end of incubation, plates were
washed three times with PBS-Tween, ABTS [2,2-azinobis(3-ethyl benz thiazoline sulfonic
acid)] substrate was added for 30 min (Thermo Scientific, Rockford, IL) and the absorbance at
405 nm was read.
Entry: Cells were plated in 96 well plates. The following day 10 μM of compound and HSV-
2 (MOI 10) were incubated for 1 h at 37˚C and subsequently added on cells for 1 h at 4˚C.
Cells were then washed and shifted at 37˚C for 1.5 h or 4 h, after they were subjected to a wash
with acidic glycine to inactivate unentered virus. Cells were then fixed with 4% paraformalde-
hyde, air dried and permeabilized with PBS-TRITON (0.5%) and then the same protocol
described for binding was followed.
Virucidal assay: Approximately 105 PFU of HSV2 plus 10 μM or different concentration of
compound were added to MEM and mixed in a total volume of 100 μL. The virus-compound
mixtures were incubated for different times at 37˚C then diluted serially to the non-inhibitory
concentration of test compound on cells or in tubes for additional 1, 2, 3 or 4 hours; the resid-
ual viral infectivity was determined by viral plaque assay.
Immunofluorescence
Cells were plated on coverslips and the following day the binding or entry protocol described
above was applied. Cells were than fixed with 4% paraformaldehyde, air dried and for entry
protocol permeabilized with PBS-TRITON. Blocking was performed with PBS-BSA 1% for 1 h
at room temperature and subsequently HSV-2 polyclonal antibody (1:250) was added on cells,
after 1 h at 37˚C the inoculum was removed and coverslips were washed with PBS-TWEEN
for 3 times. Rhodamine conjugated anti-rabbit (Santa Cruz) was then added on cells for 1 h at
37˚C following 3 washes coverslips were mounted on microscope glasses and observed with
Zeiss LSM510 fluorescence microscope (Zeiss, Oberkochen, Germany) and images were
acquired.
qPCR
Cells subjected to binding assays were then lysed and subjected to total DNA/RNA extraction
and subsequently subjected to qPCR using as primers 5’- CCGTCAGCACCTTCATCGA -3’
and 5’-CGCTGGACCTCCGTGTAGTC -3’ and as probe 5’-FAM CCACGAGATCAAGGA
CAGCGGCC-TAMRA for 40 cycles at 94˚C for 15” followed by 60˚C for 60”. The results were
normalized according to values of rnasep and the % of bound virus were measured comparing
the Δct of treated wells to wells treated with equal volume of solvent.
In vitro determination of the compound peroxidation capability
To evaluate the oxidation capability of 9d an in vitro lipoperoxidation test was carried out. In
lipid peroxidation, free radicals attack double bonds of polyunsaturated fatty acids forming
lipid hydroperoxides, which undergo homolytic scission to form a variety of cytotoxic com-
pounds, such as aldehydes. This oxidative stress plays an important role in damaging mem-
brane lipids. According to previous literature, the potential oxidative effect of 9d was evaluated
toward the oxidation of linoleic acid, a carboxylic acid with two double bonds as a model lipid
substrate. The lipoperoxidation of linoleic acid, incorporated in dipalmitoylphosphatidylcho-
line (DPPC) liposomes was determined using the TBA assay [20, 21]. DPPC liposomes were
prepared with the thin film evaporation method and used to mimic a phospholipid bilayer,
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and to dissolve linoleic acid. TBA assay, commonly used as an index of lipid peroxidation, is
based on the reactivity of malondialdehyde (MDA), a colourless end-product of degradation,
with 2-thiobarbituric acid (TBA) to produce a pink adduct (TBA-MDA-TBA) that absorbs at
535 nm. MDA is indeed one of the final products of polyunsaturated fatty acids peroxidation
in the cells and is generally considered an indicator of lipid peroxidation. MDA was detected
spectrophotometrically according to the method described by Bay et al. with the following
modifications [22].
For the TBA assay,9d compound was dissolved in DMSO at the concentration of 10 μM.
Then, 100 μl of the 9d DMSO solution were incubated at 37˚C for 30 minutes with a 0.5% lino-
leic acid containing liposome aqueous dispersion. Blank samples were prepared incubating the
liposome aqueous dispersion either with saline solution (0.9% NaCl aqueous solution) or
DMSO in the absence of 9d.
After incubation, a volume of the blank and 9d samples (0.2 mL) were withdrawn and
introduced in a glass tube closed with a screw cap and added with 0.1 mL of water, 0.2 mL of
4% w/w SDS, 1.5 mL of 1.0% w/w phosphoric acid and 1.0 mL of 0.6% w/w TBA. The mixture
was stirred and heated in water bath at 95–100˚C for 45 min to favor the formation of the com-
plex. After cooling in an ice bath, 4.0 mL of 1-butanol were added to each tube and the
TBA-MDA-TBA complex was extracted upon stirring and centrifugation. The organic super-
natant was evaluated by spectrophotometry. The calibration curve of TBA-MDA-TBA com-
plex was obtained using a MDA precursor 1,1,3,3-tetraethoxypropane. MDA can be obtained
by acid hydrolysis from 1,1,3,3-tetraethoxypropane in an equimolecular reaction. For this pur-
pose, standard solutions of 1,1,3,3-tetraethoxypropane in SDS (4% w/w) within the concentra-
tion range 5–250 μM were prepared. The solutions were subjected to TBA assay and analyzed
at spectrophotometer. The final concentration of MDA derived from the reaction of linoleic
acid, calculated exploiting the calibration curve, was expressed as micromoles of MDA per mg
of lipid substrate. To further confirm the oxidant activity of 9d the peroxidation experiment
was also carried out using a control sample containing 0.05% w/w of (±)-α-tocopherol, mole-
cule with antioxidant properties, added during the preparation of liposomes. MDA formation
was monitored in the same conditions above reported. The results are mean and SD of 3 inde-
pendent experiments.
Data analysis
Results are presented as the mean values from 2 to 6 independent experiments, in case of 2
independent experiments results are expressed ± square root of the sum of squares, in other
cases as ± SD. The EC50 values for inhibition curves were calculated by regression analysis
using the software GraphPad Prism (GraphPad Software, San Diego, California, U.S.A.) by fit-
ting a variable slope-sigmoidal dose–response curve. For binding and entry assays the signifi-
cance was analyzed with a One-way Anova followed by a Bonferroni.
Supporting information
S1 Fig. (A) Viability was evaluated after 1, 2, 3 h of exposure 24 h post-treatment. (B) Viability
was evaluated after 24, 48, 72, 96 h of exposure. % of viability were calculated through a ratio
between absorbance of wells treated with compound 9d to wells treated with equal volume of
DMSO. Results are mean and square root of the sum of squares. n = 2.
(DOCX)
S2 Fig. Virucidal activity was evaluated through incubation with 9d compound for 1h fol-
lowed by dilution in drug free medium for 1, 2, 3 or 4 h and subsequent addition on cells.
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Results are mean and SD. n = 3.
(DOCX)
Author Contributions
Conceptualization: Valeria Cagno, Maurizio Botta.
Funding acquisition: Maurizio Botta.
Investigation: Valeria Cagno, Cristina Tintori, Andrea Civra, Roberta Cavalli, Marika Tiberi,
Lorenzo Botta, Annalaura Brai, Giulio Poli.
Methodology: Valeria Cagno, Andrea Civra, Roberta Cavalli, Marika Tiberi, Lorenzo Botta,
Annalaura Brai, Giulio Poli.
Project administration: Maurizio Botta.
Supervision: Caroline Tapparel, David Lembo, Maurizio Botta.
Writing – original draft: Valeria Cagno.
Writing – review & editing: David Lembo, Maurizio Botta.
References
1. The top 10 causes of death [Internet]. World Health Organization. Available from: http://www.who.int/
news-room/fact-sheets/detail/the-top-10-causes-of-death
2. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA. 2018; 319:
1802–1813. https://doi.org/10.1001/jama.2018.3795 PMID: 29715359
3. Dengue and severe dengue [Internet]. World Health Organization. Available from: http://www.who.int/
news-room/fact-sheets/detail/dengue-and-severe-dengue
4. Wisskirchen K, Lucifora J, Michler T, Protzer U. New pharmacological strategies to fight enveloped
viruses. Trends Pharmacol Sci. 2014; 35: 470–478. https://doi.org/10.1016/j.tips.2014.06.004 PMID:
25108320
5. Mackenzie JS, Jeggo M. Reservoirs and vectors of emerging viruses. Curr Opin Virol. 2013; 3: 170–
179. https://doi.org/10.1016/j.coviro.2013.02.002 PMID: 23491947
6. Anthony SJ, Epstein JH, Murray KA, Navarrete-Macias I, Zambrana-Torrelio CM, Solovyov A, et al. A
strategy to estimate unknown viral diversity in mammals. MBio. 2013; 4:e00598–513. https://doi.org/10.
1128/mBio.00598-13 PMID: 24003179
7. Brai A, Fazi R, Tintori C, Zamperini C, Bugli F, Sanguinetti M, Stigliano E, et al. Human DDX3 protein is
a valuable target to develop broad spectrum antiviral agents. ProcNatlAcadSci U S A. 2016; 113:
5388–5393.
8. Rinaldi M.; Tintori C.; Franchi L.; Vignaroli G.; Innitzer A.; Massa S.; et al. A Versatile and Practical Syn-
thesis toward the Development of Novel HIV-1 Integrase Inhibitors ChemMedChem 2011; 6: 343–352.
https://doi.org/10.1002/cmdc.201000510 PMID: 21246739
9. Tiberi M.; Tintori C.; Ceresola E.R.; Fazi R.; Zamperini C.; Calandro P.; et al. 2-Aminothiazolones as
Anti-HIV Agents That Act as gp120-CD4 Inhibitors Antimicrob. Agents Chemother. 2014; 58: 3043–
3052.
10. Botta L, Maccari G, Calandro P, Tiberi M, Brai A, Zamperini C, et al. One drug for two targets: Biological
evaluation of antiretroviral agents endowed with antiproliferative activity. Bioorg Med Chem Lett. 2017;
27: 2502–2505. https://doi.org/10.1016/j.bmcl.2017.03.097 PMID: 28408224
11. Tintori C et al. Rhodanine derivatives as potent anti-HIV and anti-HSV microbicide PLoS One. 2018; 13:
e0198478. https://doi.org/10.1371/journal.pone.0198478 PMID: 29870553
12. Speerstra S, Chistov AA, Proskurin GV, Aralov AV, Ulashchik EA, Streshnev PP, et al. Antivirals acting
on viral envelopes via biophysical mechanisms of action. Antiviral Res. 2018; 149: 164–173. https://doi.
org/10.1016/j.antiviral.2017.11.018 PMID: 29191427
13. Pollock S, Nichita NB, Bo¨hmer A, Radulescu C, Dwek RA, Zitzmann N. Polyunsaturated liposomes are
antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells.
Proc Natl Acad Sci USA. 2010; 107: 17176–17181. https://doi.org/10.1073/pnas.1009445107 PMID:
20855621
Novel broad spectrum virucidal molecules against enveloped viruses
PLOS ONE | https://doi.org/10.1371/journal.pone.0208333 December 7, 2018 17 / 18
14. Sample CJ, Hudak KE, Barefoot BE, Koci MD, Wanyonyi MS, Abraham S, et al. A mastoparan-derived
peptide has broad-spectrum antiviral activity against enveloped viruses. Peptides. 2013; 48: 96–105.
https://doi.org/10.1016/j.peptides.2013.07.014 PMID: 23891650
15. Cooper Sandra T. and McNei Paul L. Membrane Repair: Mechanisms and Pathophysiology Physiol
Rev. 2015; 95: 1205–1240. https://doi.org/10.1152/physrev.00037.2014 PMID: 26336031
16. Cagno V, Donalisio M, Civra A, Volante M, Veccelli E, Oreste P, et al. Highly sulfated K5 Escherichia
coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tra-
cheal-bronchial histocultures. Antimicrob Agents Chemother. 2014; 58: 4782–4794. https://doi.org/10.
1128/AAC.02594-14 PMID: 24914125
17. Donalisio M, Nana HM, Ngane RAN, Gatsing D, Tchinda AT, Rovito R, et al. In vitro anti-Herpes simplex
virus activity of crude extract of the roots of Nauclea latifolia Smith (Rubiaceae). BMC Complement
Altern Med. 2013; 13:266. https://doi.org/10.1186/1472-6882-13-266 PMID: 24131916
18. Civra A, Giuffrida MG, Donalisio M, Napolitano L, Takada Y, Coulson BS, et al. Identification of Equine
Lactadherin-derived Peptides That Inhibit Rotavirus Infection via Integrin Receptor Competition. J Biol
Chem. 2015; 290:12403–14. https://doi.org/10.1074/jbc.M114.620500 PMID: 25814665
19. Cagno V, Donalisio M, Bugatti A, Civra A, Cavalli R, Ranucci E, et al. The agmatine-containing poly
(amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal
human papillomaviruses. Antimicrob Agents Chemother. 2015; 59: 5250–9. https://doi.org/10.1128/
AAC.00443-15 PMID: 26077258
20. Guille´n-Sans R, Guzma´n-Chozas M.The Thiobarbituric Acid (TBA) Reaction in Foods: A Review. Criti-
cal Reviews in Food Science and Nutrition 1998; 38: 315–350 https://doi.org/10.1080/
10408699891274228 PMID: 9626489
21. Carlotti ME, Sapino S, Marino S, Ugazio E, Trotta F, Vione D, et al. Influence of hydroxypropyl-b-cyclo-
dextrin on the photostability and antiradical activity of Trolox. J Incl Phenom Macrocycl Chem 2008; 61:
279–287.
22. Bay B-H, Lee Y-K, Tan BK-H, Ling E-A. Lipid peroxidative stress and antioxidative enzymes in brains of
milk-supplemented rats. Neuroscience Letters. 1999; 277: 127–130. PMID: 10624826
Novel broad spectrum virucidal molecules against enveloped viruses
PLOS ONE | https://doi.org/10.1371/journal.pone.0208333 December 7, 2018 18 / 18
